Tweet
BIOLINERX Ltd/S (NASDAQ:BLRX) â€“ Oppenheimer increased their FY2021 earnings per share estimates for BIOLINERX Ltd/S in a research note issued to investors on Monday, August 13th. Oppenheimer analyst M. Breidenbach now anticipates that the biotechnology company will post earnings per share of $0.11 for the year, up from their prior forecast of $0.07. Oppenheimer also issued estimates for BIOLINERX Ltd/S's FY2022 earnings at $0.12 EPS. Get BIOLINERX Ltd/S alerts:
A number of other brokerages have also recently issued reports on BLRX. HC Wainwright set a $4.00 price objective on shares of BIOLINERX Ltd/S and gave the stock a "buy" rating in a report on Tuesday, August 7th. Maxim Group reiterated a "buy" rating and issued a $2.00 price objective on shares of BIOLINERX Ltd/S in a report on Monday. ValuEngine upgraded shares of BIOLINERX Ltd/S from a "strong sell" rating to a "sell" rating in a report on Wednesday, May 2nd. Zacks Investment Research upgraded shares of BIOLINERX Ltd/S from a "sell" rating to a "hold" rating in a report on Tuesday, May 8th. Finally, MED initiated coverage on shares of BIOLINERX Ltd/S in a report on Wednesday, August 1st. They issued a "market perform" rating for the company. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. BIOLINERX Ltd/S has a consensus rating of "Buy" and a consensus price target of $2.50. Shares of NASDAQ:BLRX opened at $0.89 on Wednesday. The firm has a market capitalization of $93.68 million, a P/E ratio of -3.28 and a beta of 0.50. BIOLINERX Ltd/S has a 1 year low of $0.78 and a 1 year high of $1.34.
BIOLINERX Ltd/S (NASDAQ:BLRX) last issued its quarterly earnings data on Tuesday, May 22nd. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.01.
A hedge fund recently raised its stake in BIOLINERX Ltd/S stock. Renaissance Technologies LLC boosted its position in shares of BIOLINERX Ltd/S (NASDAQ:BLRX) by 60.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 434,700 shares of the biotechnology company's stock after acquiring an additional 164,500 shares during the period. Renaissance Technologies LLC owned 0.41% of BIOLINERX Ltd/S worth $474,000 at the end of the most recent quarter. 35.62% of the stock is owned by institutional investors.
About BIOLINERX Ltd/S
BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions